CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.27B, above the global median of $1.15B
- PositionDebt-to-equity is 3.32×, higher than 95% of its Biotechnology peers (median 0.1×)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
5.27BUSDvs all stocks (USD)
Revenue (TTM)
536.20MUSDvs all stocks (USD)
Profit Margin
-4.00%vs Biotechnology peers
Beta
1.11xvs all stocks
52-Week Change
258.47%vs all stocks
Market Capitalization
5.27BUSDvs all stocks (USD)
Enterprise Value
5.34BUSDvs all stocks (USD)
Forward P/E
11.69xvs Biotechnology peers
Price to Sales (TTM)
9.84xvs Biotechnology peers
Price to Book (MRQ)
53.10xvs Biotechnology peers
Enterprise to Revenue
9.95xvs Biotechnology peers
Gross Margin
78.96%vs Biotechnology peers
Profit Margin
-4.00%vs Biotechnology peers
Operating Margin
-29.02%vs Biotechnology peers
Return on Assets (TTM)
-6.46%vs Biotechnology peers
Return on Equity (TTM)
-69.38%vs Biotechnology peers
Revenue (TTM)
536.20MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.95USDUpdated Jul 19, 2026Quarterly Revenue Growth
55.60%vs Biotechnology peers
Gross Profit (TTM)
299.98MUSDvs all stocks (USD)
EBITDA (TTM)
22.22MUSDvs all stocks (USD)
Net Income (TTM)
-45.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
55.63%vs Biotechnology peers
Operating Cash Flow (TTM)
39.61MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-51.17MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
490.73MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
10.34MUSDFY2025 · Dec 31, 2025Gross Profit
480.39MUSDFY2025 · Dec 31, 2025Operating Income
-62.82MUSDvs all stocks (USD)
Pre-tax Income
-49.27MUSDFY2025 · Dec 31, 2025Income Tax Expense
988.00KUSDFY2025 · Dec 31, 2025Net Income
-25.55MUSDFY2025 · Dec 31, 2025EBIT
-38.52MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
22.22MUSDFY2025 · Dec 31, 2025Research & Development
206.01MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
337.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.72MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.75MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2900USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2900USDFY2025 · Dec 31, 2025Basic Shares Outstanding
89.21MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
89.21MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-50.26MUSDFY2025 · Dec 31, 2025Operating Cash Flow
20.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
93.03MUSDFY2025 · Dec 31, 2025Interest Paid
8.84MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-50.26MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
60.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
183.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.97MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-85.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.12MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-58.16MUSDFY2025 · Dec 31, 2025Purchase of Investments
-237.14MUSDFY2025 · Dec 31, 2025Sale of Investments
323.60MUSDFY2025 · Dec 31, 2025Other Investing Activity
-404.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
86.05MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-68.90MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-71.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
92.40MSharesUpdated Jul 19, 2026Float Shares
86.99MSharesUpdated Jul 19, 2026Shares Short
12.69MSharesUpdated Jul 19, 2026Short Ratio
5.25daysvs all stocks
Short % of Shares Outstanding
17.84%vs all stocks
% Held by Insiders
0.80%vs all stocks
% Held by Institutions
113.77%vs all stocks
Total Cash (MRQ)
264.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.85USDUpdated Jul 19, 2026Total Debt (MRQ)
327.66MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.32xvs Biotechnology peers
Current Ratio (MRQ)
3.13xvs Biotechnology peers
Book Value per Share (MRQ)
1.07USDUpdated Jul 19, 2026Total Assets
604.44MUSDvs all stocks (USD)
Total Current Assets
437.56MUSDFY2025 · Dec 31, 2025Total Liabilities
490.36MUSDFY2025 · Dec 31, 2025Total Non-current Assets
166.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
330.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
159.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.03MUSDFY2025 · Dec 31, 2025Other Short-term Investments
229.76MUSDFY2025 · Dec 31, 2025Accounts Receivable
80.13MUSDFY2025 · Dec 31, 2025Inventory
5.88MUSDFY2025 · Dec 31, 2025Accounts Payable
24.80MUSDFY2025 · Dec 31, 2025Short-term Debt
5.88MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.19MUSDFY2025 · Dec 31, 2025Long-term Debt
322.86MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
7.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.47BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
114.83MUSDvs all stocks (USD)
52-Week Low
15.03USDUpdated Jul 19, 202652-Week High
60.10USDUpdated Jul 19, 202652-Week Change
258.47%vs all stocks
Beta
1.11xvs all stocks
50-Day MA
50.46USDUpdated Jul 19, 2026200-Day MA
36.81USDUpdated Jul 19, 2026Avg 10-Day Volume
1.30MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.04MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.5000USDUpdated Jul 19, 2026Other Income / Expense
11.58MUSDFY2025 · Dec 31, 202512 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
How does this company use capital?
Diagnostic
Efficiency from Aging Assets
Revenue per asset reads high, partly because those assets are largely written down.
Reads
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Depreciation Intensity
Most of its equipment is already written off, and depreciation is larger against its cash flow than its industry's.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 3.32×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 3.32Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 53.1×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 53.10Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.56Receivables vs revenue divergence: 2.56
High gross margins eroded by operating costsNotable
Gross Margin: 0.79Profit Margin: -0.04
Significant cash reserves alongside high leverageNotable
Cash (USD): 264,676,000Total Debt (USD): 327,662,016Debt-to-Equity: 3.32
Financial Health
Altman Z-Score 4.19: safe zoneNotable
Altman Z-Score: 4.19
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.27B, above the global median of $1.15BNotable
Market cap (USD): 5,273,627,642Global Median: 1,146,734,693.424
Revenue is $536.2M, above the global median of $520.53MNotable
Revenue (USD): 536,195,008Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Changchun High-Tech Industry Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Dong-E-E-JiaoCo Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Inox India Ltd.
4 interpretationsRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated Turnover
Puma Biotechnology Inc.
5 interpretationsDebt Falling While Share Count RisesEfficiency from Aging AssetsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated Turnover
Shriram Pistons & Rings Ltd.
2 interpretationsRevenue Growing With Receivables GrowingIndustry-Benchmarked ROA and Margin Elevated